ArticleJournal of cellular and molecular medicine2025
OVOL1 Promotes Proliferation and Metastasis of Non-Small Cell Lung Cancer by Regulating APOE-Mediated Cholesterol Metabolism.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apolipoprotein E promotes papillary thyroid carcinoma progression by activating PINK1/Parkin-mediated mitophagy.Translational cancer research · 2026Article
- Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is a highly lethal malignant tumour characterised by its resistance to treatment, often due to metabolic reprogramming. Despite this, the underlying mechanisms by which aberrant cholesterol metabolism influences the development and progression of NSCLC remain unclear. In our study, we observed that OVOL1 is significantly upregulated in NSCLC and is correlated with a poor prognosis. Furthermore, our functional assays revealed that OVOL1 enhances the proliferation and metastasis of NSCLC cells both in vitro and in vivo. Mechanistically, OVOL1 was found to modulate cholesterol reprogramming and increase the expression of APOE, thereby intensifying cholesterol metabolism and facilitating cell migration and invasion. In conclusion, our findings suggest that OVOL1 acts as an oncogene in NSCLC, promoting tumour growth and metastasis through the enhancement of cholesterol metabolism. This underscores the potential of OVOL1 as a therapeutic target for the treatment of NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.